+

WO2009106019A3 - Compuestos quimicos con accion antiviral contra virus dengue y otros flavivirus - Google Patents

Compuestos quimicos con accion antiviral contra virus dengue y otros flavivirus Download PDF

Info

Publication number
WO2009106019A3
WO2009106019A3 PCT/CU2009/000002 CU2009000002W WO2009106019A3 WO 2009106019 A3 WO2009106019 A3 WO 2009106019A3 CU 2009000002 W CU2009000002 W CU 2009000002W WO 2009106019 A3 WO2009106019 A3 WO 2009106019A3
Authority
WO
WIPO (PCT)
Prior art keywords
dengue virus
flaviviruses
chemical compounds
activity against
antiviral activity
Prior art date
Application number
PCT/CU2009/000002
Other languages
English (en)
French (fr)
Other versions
WO2009106019A2 (es
Inventor
Yuliet Mazola Reyes
Glay Chinea Santiago
Osmany Guirola Cruz
Roberto Vera Alvarez
Vivian Huerta Galindo
Noralvis Fleitas Salazar
Alexis Musacchio Lasa
Original Assignee
Centro De Ingenieria Genetica Y Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Ingenieria Genetica Y Biotecnologia filed Critical Centro De Ingenieria Genetica Y Biotecnologia
Priority to JP2010547941A priority Critical patent/JP5400067B2/ja
Priority to US12/919,416 priority patent/US8722742B2/en
Priority to MX2010009563A priority patent/MX2010009563A/es
Priority to EP09714439.8A priority patent/EP2258356B1/en
Priority to ES09714439.8T priority patent/ES2647506T3/es
Priority to AU2009218960A priority patent/AU2009218960B2/en
Priority to CN200980113787XA priority patent/CN102006865B/zh
Priority to BRPI0908489-4A priority patent/BRPI0908489A2/pt
Priority to CA2716971A priority patent/CA2716971C/en
Publication of WO2009106019A2 publication Critical patent/WO2009106019A2/es
Publication of WO2009106019A3 publication Critical patent/WO2009106019A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Uso de compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus Dengue. Particularmente, mediante la interferencia o modulación de varias etapas del ciclo de replicación viral relacionadas con la entrada del virus a las células dianas y el ensamblaje de los viriones progenie. Además, del uso de dichas composiciones farmacéuticas para el tratamiento profiláctico y/o terapéutico de Ia infección causada por los cuatro serotipos del virus de Dengue y por otros flavivirus.
PCT/CU2009/000002 2008-02-29 2009-02-27 Compuestos quimicos con accion antiviral contra virus dengue y otros flavivirus WO2009106019A2 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2010547941A JP5400067B2 (ja) 2008-02-29 2009-02-27 デングウイルス及びその他のフラビウイルスに対して抗ウイルス活性を有する化合物
US12/919,416 US8722742B2 (en) 2008-02-29 2009-02-27 Chemical compounds having antiviral activity against Dengue virus and other Flaviviruses
MX2010009563A MX2010009563A (es) 2008-02-29 2009-02-27 Compuestos quimicos con accion antiviral contra virus de dengue y otros flavivirus.
EP09714439.8A EP2258356B1 (en) 2008-02-29 2009-02-27 Chemical compounds having antiviral activity against dengue virus and other flaviviruses
ES09714439.8T ES2647506T3 (es) 2008-02-29 2009-02-27 Compuestos químicos que tienen actividad antiviral contra el virus dengue y otros flavivirus
AU2009218960A AU2009218960B2 (en) 2008-02-29 2009-02-27 Chemical compounds having antiviral activity against dengue virus and other flaviviruses
CN200980113787XA CN102006865B (zh) 2008-02-29 2009-02-27 化学化合物在制备用于减弱或抑制黄病毒属病毒感染的药物组合物中的用途
BRPI0908489-4A BRPI0908489A2 (pt) 2008-02-29 2009-02-27 uso de compostos químicos e método para desenhar compostos químicos que atenuam ou inibem a infecção pelo vírus da dengue
CA2716971A CA2716971C (en) 2008-02-29 2009-02-27 Chemical compounds having antiviral activity against dengue virus and other flaviviruses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2008-0028 2008-02-29
CU20080028A CU20080028A6 (es) 2008-02-29 2008-02-29 Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus

Publications (2)

Publication Number Publication Date
WO2009106019A2 WO2009106019A2 (es) 2009-09-03
WO2009106019A3 true WO2009106019A3 (es) 2010-01-28

Family

ID=40972816

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU2009/000002 WO2009106019A2 (es) 2008-02-29 2009-02-27 Compuestos quimicos con accion antiviral contra virus dengue y otros flavivirus

Country Status (11)

Country Link
US (1) US8722742B2 (es)
EP (1) EP2258356B1 (es)
JP (1) JP5400067B2 (es)
CN (1) CN102006865B (es)
AU (1) AU2009218960B2 (es)
BR (1) BRPI0908489A2 (es)
CA (1) CA2716971C (es)
CU (1) CU20080028A6 (es)
ES (1) ES2647506T3 (es)
MX (1) MX2010009563A (es)
WO (1) WO2009106019A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109384727B (zh) * 2017-08-10 2023-07-28 中国科学院上海药物研究所 酞嗪酮类化合物、其制备方法、药物组合物及用途

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518960B2 (en) * 2007-05-23 2013-08-27 Siga Technologies, Inc. Antiviral drugs for treatment or prevention of dengue infection
CN102731394A (zh) * 2011-04-12 2012-10-17 中国科学院上海药物研究所 取代的喹啉-2-甲醛-苯腙类化合物及其制备方法和用途
EA026368B1 (ru) 2011-12-21 2017-03-31 Новира Терапьютикс, Инк. Противовирусные агенты против гепатита в
CN103183631B (zh) * 2011-12-28 2016-08-24 天津市国际生物医药联合研究院 靛红-5-磺酰胺类衍生物及其在制备治疗非典型性肺炎的药物中的应用
WO2013192165A2 (en) 2012-06-20 2013-12-27 University Of Kansas Compounds and methods for activating the apoptotic arm of the unfolded protein response
CA3139033A1 (en) 2012-08-22 2014-02-27 Cornell University Methods for inhibiting fascin
BR112015004205B1 (pt) 2012-08-28 2022-02-01 Janssen Sciences Ireland Uc Sulfamoil-arilamidas, seu uso das mesmas como medicamentos para o tratamento da hepatite b, composição farmacêutica que as compreende e produto
CU24188B1 (es) * 2012-12-27 2016-07-29 Ct De Ingeniería Genética Y Biotecnología Composición vacunal contra el virus dengue
BR112015020242A2 (pt) 2013-02-28 2017-07-18 Janssen Sciences Ireland Uc sulfamoil-arilamidas e seu uso como medicamentos para o tratamento da hepatite b
AU2014247138B2 (en) 2013-04-03 2018-06-28 Janssen Sciences Ireland Uc N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
MX366787B (es) 2013-05-17 2019-07-23 Janssen Sciences Ireland Uc Derivados de sulfamoiltiofenamida y su uso como medicamentos para tratar la hepatitis b.
UA118680C2 (uk) 2013-07-25 2019-02-25 ЯНССЕН САЙЄНСЕЗ АЙРЛЕНД ЮСі Похідні заміщеного гліоксамідом піроламіду та їхнє застосування як лікарських препаратів для лікування гепатиту в
CA2923712C (en) 2013-10-23 2021-11-02 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
CN106232136A (zh) 2014-02-05 2016-12-14 诺维拉治疗公司 用于治疗hbv感染的联合疗法
CN105980378B (zh) 2014-02-06 2019-09-27 爱尔兰詹森科学公司 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
CN106232583B (zh) 2014-02-20 2020-04-24 康奈尔大学 用于抑制肌成束蛋白的化合物和方法
CU20140026A7 (es) * 2014-03-03 2015-11-27 Ct De Ingeniería Genética Y Biotecnología Biocubafarma Péptidos horquilla beta con propiedades antivirales contra el virus dengue
MX2016015247A (es) * 2014-05-23 2017-02-23 Hoffmann La Roche Derivados de benceno-sulfonamida y su uso como moduladores del receptor c huerfano relacionado a acido retinoico (rorc).
CN107405392B (zh) * 2015-02-09 2021-05-18 中央研究院 用于增强对抗登革病毒的安全性及免疫力的抗原表位替换的疫苗
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CA3021068A1 (en) 2016-04-15 2017-10-19 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
SI3518948T1 (sl) * 2016-10-03 2023-09-29 Ottawa Hospital Research Institute Kompozicije in metode za povečanje rasti, širjenja ter onkolitične in imunoterapevtske učinkovitosti onkolitičnih RNA-virusov
CN108299280A (zh) * 2018-01-19 2018-07-20 天津国际生物医药联合研究院 对混合谱系白血病关键蛋白具有抑制作用的靛红-5-磺酰胺类抑制剂
AU2019235522A1 (en) 2018-03-14 2020-09-03 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
JP7357934B2 (ja) 2018-04-12 2023-10-10 パーデュー・リサーチ・ファウンデーション ベンズアミド抗菌剤
KR20210130753A (ko) 2019-02-22 2021-11-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Hbv 감염 또는 hbv-유발성 질환의 치료에 유용한 아미드 유도체
KR20220005549A (ko) 2019-05-06 2022-01-13 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Hbv 감염 또는 hbv-유도성 질환의 치료에 유용한 아미드 유도체
CN111346079B (zh) * 2020-02-24 2023-06-20 南方医科大学 细菌dna促旋酶抑制剂brd7716作为治疗和/或预防登革病毒感染的药物及其制药用途
EP4157263A4 (en) * 2020-05-26 2024-09-11 The Regents Of The University Of Michigan Mitochondrial targeting compounds for the treatment of associated diseases
EP4479054A1 (en) * 2022-02-16 2024-12-25 Nico Therapeutics, Inc. Compounds, compositions, and methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031814A1 (es) * 1997-01-15 1998-07-23 Centro De Ingenieria Genetica Y Biotecnologia (Cigb) Epitopes de la proteina pre-m/m del virus del dengue, peptidos sinteticos
WO2003008571A2 (es) * 2001-07-16 2003-01-30 Centro De Ingenieria Genetica Y Biotecnologia Cadenas quiméricas codificantes para proteínas inductoras de efectos contra virus
EP2022506A2 (en) * 2006-04-28 2009-02-11 Centro De Ingenieria Genetica Y Biotecnologia Method for the treatment of flavivirus infection, molecules and uses thereof
WO2009032975A1 (en) * 2007-09-07 2009-03-12 Mevlabs, Inc. Formulations and devices for delivering compounds to arthropods and microorganisms within arthopods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002501A2 (en) * 2003-04-22 2005-01-13 Children's Medical Center Corporation Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031814A1 (es) * 1997-01-15 1998-07-23 Centro De Ingenieria Genetica Y Biotecnologia (Cigb) Epitopes de la proteina pre-m/m del virus del dengue, peptidos sinteticos
WO2003008571A2 (es) * 2001-07-16 2003-01-30 Centro De Ingenieria Genetica Y Biotecnologia Cadenas quiméricas codificantes para proteínas inductoras de efectos contra virus
EP2022506A2 (en) * 2006-04-28 2009-02-11 Centro De Ingenieria Genetica Y Biotecnologia Method for the treatment of flavivirus infection, molecules and uses thereof
WO2009032975A1 (en) * 2007-09-07 2009-03-12 Mevlabs, Inc. Formulations and devices for delivering compounds to arthropods and microorganisms within arthopods

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CUSHION, MELANIE T. ET AL: "A cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , 41(2), 379-384 CODEN: AMACCQ; ISSN: 0066-4804, 1997, XP008114068 *
MARRERO-PONCE, YOVANI ET AL: "Ligand-Based Virtual Screening and in Silico Design of New Antimalarial Compounds Using Nonstochastic and Stochastic Total and Atom-Type Quadratic Maps", JOURNAL OF CHEMICAL INFORMATION AND MODELING , 45(4), 1082-1100 CODEN: JCISD8; ISSN: 1549-9596, 2005, XP008114058 *
SANTOS J L ET AL: "Synthesis and in vitro anti Mycobacterium tuberculosis activity of a series of phthalimide derivatives", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 17, no. 11, 1 June 2009 (2009-06-01), pages 3795 - 3799, XP026118924, ISSN: 0968-0896, [retrieved on 20090503] *
VILAR SANTIAGO ET AL: "Probabilistic Neural Network Model for the In Silico Evaluation of Anti- HIVActivity and Mechanism of Action", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 49, no. 3, 9 February 2006 (2006-02-09), pages 1118 - 1124, XP008089363, ISSN: 0022-2623 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109384727B (zh) * 2017-08-10 2023-07-28 中国科学院上海药物研究所 酞嗪酮类化合物、其制备方法、药物组合物及用途

Also Published As

Publication number Publication date
AU2009218960B2 (en) 2013-06-27
EP2258356A2 (en) 2010-12-08
ES2647506T3 (es) 2017-12-21
MX2010009563A (es) 2010-09-24
WO2009106019A2 (es) 2009-09-03
US20110065686A1 (en) 2011-03-17
JP2011513250A (ja) 2011-04-28
CA2716971A1 (en) 2009-09-03
AU2009218960A1 (en) 2009-09-03
CN102006865B (zh) 2013-04-24
CN102006865A (zh) 2011-04-06
US8722742B2 (en) 2014-05-13
CU20080028A6 (es) 2011-02-24
JP5400067B2 (ja) 2014-01-29
EP2258356B1 (en) 2017-09-27
CA2716971C (en) 2016-05-10
BRPI0908489A2 (pt) 2018-03-27

Similar Documents

Publication Publication Date Title
WO2009106019A3 (es) Compuestos quimicos con accion antiviral contra virus dengue y otros flavivirus
WO2010118367A3 (en) Antiviral pyrimidines
WO2009091388A3 (en) Triazines and related compounds having antiviral activity, compositions and methods thereof
MY202109A (en) Viral replication inhibitors
WO2011106992A8 (en) Inhibitors of hepatitis c virus ns5b polymerase
MX2010001733A (es) Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis.
WO2007041487A3 (en) Viral peptides and their use to inhibit viral infections against viruses of the flaviridae family
WO2012083048A3 (en) Anti-viral compounds
WO2012083053A3 (en) Anti-viral compounds
CA2862755A1 (en) Antiviral compounds with a dibenzooxaheterocycle moiety
WO2008021936A3 (en) Hepatitis c virus inhibitors
WO2008127364A3 (en) Antiviral compounds and use thereof
EP2853531A3 (en) Antiviral compounds
WO2011041713A3 (en) Piperazinyl antiviral agents
WO2008133704A3 (en) Antimicrobial and antiviral compounds and methods for their use
WO2007084435A8 (en) Methods for treating hepatitis c
WO2012083061A3 (en) Anti-viral compounds
WO2010055164A3 (en) Isoquinolone derivatives as inhibitors of plavivirus replication
WO2013048153A3 (ko) 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자
MY194294A (en) Novel viral replication inhibitors
WO2008086042A3 (en) Preventing infection by a measles or respiratory syncytial virus
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
WO2009029384A3 (en) Compounds for the treatment of hepatitis c
WO2012083058A3 (en) Anti-viral compounds
PH12014500385A1 (en) Benzofuran compounds for the treatment of hepatitis c virus infections

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980113787.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2716971

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2009714439

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009714439

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010547941

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/009563

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009218960

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1914/MUMNP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2009218960

Country of ref document: AU

Date of ref document: 20090227

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12919416

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0908489

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100827

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载